BCL-2 immunoreactivity increases with severity of CIN: A study of normal cervical epithelia, CIN, and cervical carcinoma

Journal of Pathology

Volumn 179, Issue 1, 1996, Pages 26-30

  Ter Harmsel, Bram ^a   Smedts, Frank ^b   Kuijpers, Johan ^a   Jeunink, Marcel ^b   Trimbos, Baptist ^c   Ramaekers, Frans ^d  

^a Reinier de Graaf Gasthuis ^*  (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Apoptosis; BCL 2; Carcinoma; Cervix; Dysplasia; Immunocytochemistry; Prognosis

Indexed keywords

PROTEIN BCL 2;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; DISEASE PROGRESSION; EPITHELIUM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; METAPLASIA; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; UTERINE CERVICAL NEOPLASMS;

EID: 0029995825     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199605)179:1<26::AID-PATH516>3.0.CO;2-E     Document Type: Article

References (14)

1. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14,18) chromosome translocation. Science 1984; 226: 1097-1099.
2. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas' clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985; 41: 899-906.
3. Nuñez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated BCL-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990; 144: 3602-3610
4. Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ BCL-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-336.
5. Pezella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the BCL-2 oncogene protein is not specific for the 14,18 chromosomal translocation. Am J Pathol 1990; 137: 225-232
6. LeBrun DP, Warnke RA, Cleary ML. Expression of BCL-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993; 142: 743-753.
7. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991, 88: 6961-6965.
8. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994; 424: 47-51.
9. Pezella F, Turley H, Kuzu I, et al. BCL-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993, 329: 690-694
10. Vooijs GP Benign proliferative reactions, intraepithelial neoplasia and invasive cancer of the uterine cervix. In. Bibbo B, ed Comprehensive Cytopathology. Philadelphia W. B. Saunders, 1991, 153-230.
11. Smedts F, Ramaekers FCS, Vooijs GP. The dynamics of keratin expression in malignant transformation of cervical epithelium a review. Obstet Gynecol 1993; 82: 465-474.
12. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dyaplasia during long-term follow-up. Obstet Gynecol 1986; 67: 665-669
13. Swanson PE, Humphrey PA, Dehner LP Immunoreactivity for bcl-2 protein in peripheral primitive neuroectodermal tumors Appl Immunohistochem 1993; 1: 182-187
14. Robbins SL. Neoplasia. In: Cotran RS, Kumar V, Robbins SL, eds Pathologic Basis of Disease. Philadelphia: W. B Saunders, 1989; 239-305